Comparative Pharmacology
Head-to-head clinical analysis: BENSULFOID versus CENTANY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENSULFOID versus CENTANY.
BENSULFOID vs CENTANY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unknown; may inhibit Na+/K+-ATPase pump and increase renal sodium excretion
Mupirocin binds to isoleucyl-tRNA synthetase, inhibiting bacterial protein synthesis.
Bensulfoid: not a recognized drug. No data available.
Apply a thin layer to affected area twice daily for 10 days. For perioral dermatitis, apply once daily.
None Documented
None Documented
Terminal elimination half-life: 12-18 hours in adults with normal renal function; prolonged to 24-48 hours in moderate renal impairment (CrCl 30-50 mL/min).
8-10 minutes in serum; prolonged to 15-20 minutes in patients with renal impairment. Clinical context: Rapidly cleared, infrequent dosing intervals (e.g., every 20 minutes during procedure).
Renal excretion of unchanged drug: 70-80%; biliary/fecal: 15-20%; metabolic inactivation accounts for the remainder.
Primarily excreted unchanged in urine via glomerular filtration and tubular secretion (85-90% renal); minor biliary/fecal elimination (<5%).
Category C
Category C
Topical Antibiotic
Topical Antibiotic